These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22273086)

  • 21. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C;
    JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri
    Butzkueven H; Trojano M; Kappos L; Spelman T; Wiendl H; Rosales K; Su R; Licata S; Ho PR; Campbell N
    Mult Scler; 2021 Mar; 27(3):410-419. PubMed ID: 32406786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
    Ryerson LZ; Foley J; Chang I; Kister I; Cutter G; Metzger RR; Goldberg JD; Li X; Riddle E; Smirnakis K; Kasliwal R; Ren Z; Hotermans C; Ho PR; Campbell N
    Neurology; 2019 Oct; 93(15):e1452-e1462. PubMed ID: 31515290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite.
    Costelloe L; O'Rourke K; McGuigan C; Walsh C; Tubridy N; Hutchinson M
    Mult Scler; 2008 Mar; 14(2):255-8. PubMed ID: 17942522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
    Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
    CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The toronto observational study of natalizumab in multiple sclerosis.
    Krysko KM; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):422-8. PubMed ID: 21515500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natalizumab and HSV meningitis.
    Shenoy ES; Mylonakis E; Hurtado RM; Venna N
    J Neurovirol; 2011 Jun; 17(3):288-90. PubMed ID: 21487835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J
    Am J Manag Care; 2010 Jun; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
    Friend S; Richman S; Bloomgren G; Cristiano LM; Wenten M
    BMC Neurol; 2016 Aug; 16(1):150. PubMed ID: 27552976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NAPS-MS: Natalizumab Effects on Parameters of Sleep in Patients with Multiple Sclerosis.
    Sater RA; Gudesblatt M; Kresa-Reahl K; Brandes DW; Sater P
    Int J MS Care; 2016; 18(4):177-82. PubMed ID: 27551242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2018 Feb; 20():93-99. PubMed ID: 29353737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
    Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
    Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA; Sandrock A
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany.
    Watson C; Prosser C; Braun S; Landsman-Blumberg PB; Gleissner E; Naoshy S
    Clinicoecon Outcomes Res; 2017; 9():85-97. PubMed ID: 28203098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A self-management programme to reduce falls and improve safe mobility in people with secondary progressive MS: the BRiMS feasibility RCT.
    Gunn H; Andrade J; Paul L; Miller L; Creanor S; Stevens K; Green C; Ewings P; Barton A; Berrow M; Vickery J; Marshall B; Zajicek J; Freeman J
    Health Technol Assess; 2019 Jun; 23(27):1-166. PubMed ID: 31217069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis.
    Kim KH; Kim SH; Park NY; Hyun JW; Kim HJ
    Front Neurol; 2021; 12():714941. PubMed ID: 34305808
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.